SRC and ovarian cancer: Combining Dasatinib with Dox has been shown to synergistically inhibit growth as well as migration and invasion of MDA-MB-231 cells [73] and had a synergistic anti-proliferative effect in a highly tumorigenic ovarian cancer cell line that had high Src levels [74].